# A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

> **NCT07232719** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 250 (estimated)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** Retatrutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07232719
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-17
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232719, "A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07232719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*